Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DAN…

Overview of attention for article published in BMC Cancer, March 2022

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Good Attention Score compared to outputs of the same age and source (70th percentile)

Mentioned by

twitter: 2 X users

reddit: 1 Redditor

Citations

dimensions_citation: 2 Dimensions

Readers on

mendeley: 15 Mendeley

Summary X Reddit Dimensions citations

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 940 followers.

New article: Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study) https://t.co/da4WZ1SU6E #lungcan

21 Mar 2022

Reply Repost Favourite

Rationale and design of a phase II trial of dacomitinib in advanced non-small cell lung cancer patients with uncommon epidermal growth factor receptor mutations: a prospective and single arm study (DANCE study)https://t.co/u8G6zAeGRi

21 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.